Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
about
sameAs
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsStructural Model of the Extracellular Assembly of the TCR-CD3 Complex.Conserved structural elements in the V3 crown of HIV-1 gp120Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesHuman Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaIsolation of monoclonal antibodies with predetermined conformational epitope specificityHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentVisualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Statistical approaches to analyzing HIV-1 neutralizing antibody assay dataHIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell ActivationComparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesA recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodiesCross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subjectPlasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialStructural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesEnzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodiesMolecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designA mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine developmentCharacterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
P2860
Q24635002-BF42DF19-F694-4877-B204-5BCA21476B01Q27319571-DE35C63B-B443-438E-8471-2A786DEE21E5Q27663325-B1E07A9F-54D5-4047-A618-3D1424FD0B58Q27665884-A25DB960-E020-4262-A1E2-048C0B49754BQ27674878-46AD1CEC-AFE7-400B-BA0E-3BCAD69E3887Q27676155-575DD94F-B9FC-444D-8D52-B1B3FD733545Q27677941-8B279C2C-7972-47BF-A0F0-C828FF78581DQ27679559-6ABBD4A0-37B5-44B2-B477-2625217DFD33Q28477253-A33584E1-F703-4D04-8A42-4816983A08D0Q28483205-D9583D38-A260-4886-9CAE-5F105EA569C4Q28728170-38F391F4-C016-42E9-9162-A85924CF3DEDQ30355260-FC969B4B-D823-470B-99BC-99C143454FBDQ30603475-62B9BEA1-92B8-4E64-9210-4CCB4D714A37Q30784057-EFCE26E6-7B64-40D7-8F75-806FFE89C4E9Q30828739-1C3234C4-A032-4E5F-B3A1-B1B5126B42F2Q30994182-4F821FD1-0128-4C42-988E-EA0368F390A2Q33786140-5470CD65-25CB-4DA3-9350-446D390032FCQ33867353-80058FE1-D4A1-48FC-97DE-B12CD3139E9BQ34017550-122D2127-8987-4957-BEBA-74C2D7407CEBQ34023249-4F17CA53-D3FD-49AB-955F-135DC8D8DD70Q34128200-9EDA858C-0A32-4B0C-B6EE-6426307869ADQ34164923-626DFCDF-9E8F-4F97-8756-75F49FEB0C5CQ34204047-3DA06CC9-29D6-4E47-91F5-22097672BB1EQ34225659-BF843316-6882-4244-891F-225B7E645391Q34326222-82D39132-21C1-498E-A345-B20B434AF0D7Q34374835-567BE909-967B-4450-8BE7-B8F6E359AFFBQ34402934-03A3E1B3-EE35-49FB-AFF4-F096C9B76EB7Q34463861-B0145FBB-B6A1-4925-B4B7-9F7D84172F58Q34499013-E482D3D0-76E1-4172-8599-292807D49C23Q34533041-F70CF468-F569-4774-9E86-0FB25874CB07Q34562259-FF555597-1CB2-4971-9641-C222784991B5Q34847834-0ADCF10C-D11C-4ECF-AAC1-5D2FCD0D071DQ34948847-0FEC36FD-AFCE-4245-B193-5742574705E9Q35076987-25E5D794-A99E-4968-8E22-A7D152FF6F89Q35108505-B53B8167-E118-42AB-BD4C-CC92CC97CBF6Q35161426-10C7A2CE-476B-4326-8444-9B68178EBCC6Q35196671-D630FC21-F8D8-49EA-B6A8-7385ACAC0492Q35298899-2B7F08EF-85DB-45E4-BA83-954429CA59DAQ35651494-0C8F47EA-61F3-445F-A35E-719CE1319030Q35706462-C9A9DCF9-8CAA-421F-802B-AF42D5C2ED7B
P2860
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@ast
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@en
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@nl
type
label
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@ast
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@en
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@nl
prefLabel
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@ast
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@en
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@nl
P2093
P2860
P1433
P1476
Anti-V3 monoclonal antibodies ...... gainst multiple HIV-1 subtypes
@en
P2093
Blake Wood
Catarina E Hioe
Constance Williams
Michael S Seaman
Steve Self
Susan Zolla-Pazner
Terri Wrin
Xuesong Yu
P2860
P304
P356
10.1371/JOURNAL.PONE.0010254
P407
P577
2010-04-21T00:00:00Z